J Clin Neurol.  2019 Apr;15(2):259-261. 10.3988/jcn.2019.15.2.259.

Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and Intravenous Immunoglobulin

• Kim A
• Keam B
• Cheun H
• Lee ST
• Gook HS
• Han MK

• KMID: 2467743
• DOI: http://doi.org/10.3988/jcn.2019.15.2.259

Abstract

No abstract available.

MeSH Terms

Encephalitis*
Immunoglobulins*
Immunoglobulins

Figure

• 

  Fig. 1 Clinical course of the patient. ABx: antibiotics, ACV: acyclovir, AED: anti-epileptic drug, CRP: C-reactive protein, CSF: cerebrospinal fluid, DWI: diffusion-weighted image, EEG: electroencephalography, FLAIR: fluid-attenuated inversion recovery, GD-enhanced T1: gadolinium-enhanced T1, GTCS: generalized tonic-clonic seizure, IVIG: intravenous immunoglobulin, L: lymphocytes, LCS: lacosamide, LEV: levetiracetam, MDZ CIV: continuous intravenous infusion of midazolam, O: other cells, P: polymorphonuclear cells, PRP: perampanel, TPM: topiramate, VPA: valproic acid, WBC: white blood cells.

Reference

1. Krishnamurthy A, Jimeno A. Atezolizumab: a novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. Drugs Today (Barc). 2017; 53:217–237. PMID: 28492290.

2. Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, et al. Neurologic complications of immune checkpoint inhibitors. J Neurooncol. 2018; 137:601–609. PMID: 29332184.

3. Food and Drug Administration. TECENTRIQ® (atezolizumab) injection, for intravenous use [Internet]. USA: Silver Spring: Food and Drug Administration;2018. cited 2018 Sep 1. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761034s009lbl.pdf.

4. Blackmon JT, Viator TM, Conry RM. Central nervous system toxicities of anti-cancer immune checkpoint blockade. J Neurol Neuromed. 2016; 1:39–45.

5. Ito M, Fujiwara S, Fujimoto D, Mori R, Yoshimura H, Hata A, et al. Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. Ann Oncol. 2017; 28:2318–2319. PMID: 28911080.

6. Williams TJ, Benavides DR, Patrice KA, Dalmau JO, De Ávila AL, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016; 73:928–933. PMID: 27271951.

7. Maurice C, Schneider R, Kiehl TR, Bavi P, Roehrl MH, Mason WP, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res. 2015; 3:1299–1302. PMID: 26419960.

8. Hottinger AF, De Micheli R, Guido V, Karampera A, Hagmann P, Du Pasquier R. Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis. Neurol Neuroimmunol Neuroinflamm. 2018; 5:e439. PMID: 30465016.

9. Levine JJ, Somer RA, Hosoya H, Squillante C. Atezolizumab-induced encephalitis in metastatic bladder cancer: a case report and review of the literature. Clin Genitourin Cancer. 2017; 15:e847–e849. PMID: 28372981.

10. Laserna A, Tummala S, Patel N, El Hamouda DEM, Gutiérrez C. Atezolizumab-related encephalitis in the intensive care unit: case report and review of the literature. SAGE Open Med Case Rep. 2018; 6:2050313X18792422.

11. Sacco E, Pinto F, Sasso F, Racioppi M, Gulino G, Volpe A, et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int. 2009; 83:1–11. PMID: 19641351.

12. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003; 349:1543–1554. PMID: 14561798.

13. Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, et al. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther. 2017; 102:305–312. PMID: 27981577.